An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Trial Profile

An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Brain injuries
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CHIC
  • Sponsors NeuroVive Pharmaceutical
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 May 2017 Results published in a NeuroVive Pharmaceuticals media release.
    • 23 May 2017 According to a NeuroVive Pharmaceuticals media release, status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top